Implantable device and use therefor

• US 5,704,910 A
• Filed: 06/05/1995
• Issued: 01/06/1998
• Est. Priority Date: 06/05/1995
• Status: Expired due to Term

• Current Assignee: Renamed Biologics, Inc.
• Original Assignee: Nephros Therapeutics, Inc. (Renamed Biologics, Inc.)
• Inventors: Humes, H. David
• Primary Examiner(s): McDermott, Corrine M.
• Assistant Examiner(s): Blyveis, Deborah
• Application Number:
  US08/461,042
• Time in Patent Office: 946 Days
• Field of Search: 604/890.1, 604/891.1, 604/93, 604/264, 604/52, 606/198, 606/200
• US Class Current: 604/502
• CPC Class Codes: A61F 2/0105 Open ended, i.e. legs gathered only at one side
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61F 2002/016 made from wire-like elements
• CPC Class Codes: A61F 2230/005 Rosette-shaped, e.g. star-shaped
• CPC Class Codes: A61F 2230/0067 conical
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50

Abstract

Disclosed is an implantable device for delivering a pre-selected molecule, for example, a hormone, into a mammal'"'"'s systemic circulation. The device comprises a blood permeable element that can be anchored to an inner wall of an intact blood vessel. The device also comprises a capsule that is held in place within the blood vessel by the anchored blood permeable element. The capsule encloses viable cells which produce and secrete the pre-selected molecule into blood passing the capsule. The invention also provides a minimally invasive method for percutaneously introducing into a preselected blood vessel the device of the invention.

Claims

1. A method for percutaneously introducing into a blood vessel a device for delivering a pre-selected molecule into systemic circulation, the method comprising the steps of:

(a) anchoring a blood permeable element to an inner wall of all intact blood vessel, the element when anchored permitting blood in the vessel to pass therethrough;

(b) introducing at a location upstream of the dement a capsule comprising viable calls which produce and secrete the pre-selected molecule; and

(c) permitting the capsule, impelled by blood flow, to be captured by the element.

2. The method of claim 1, comprising the additional step, prior to step (a), of introducing the element into the vessel via a catheter.

3. The method of claim 1 or 2, wherein the capsule is introduced into the vessel by a catheter.

4. The method of claim 3, wherein the element is anchored in a vein.

5. The method of claim 4, wherein the vein is selected from the group consisting of an inferior vena cava, a superior vena cava, a portal vein and a renal vein.

6. The method of claim 1, wherein the pre-selected molecule is a hormone.

7. The method of claim 6, wherein the hormone is selected from the group consisting of erythropoietin and insulin.

8. The method of claim 1, wherein the element comprises a plurality of filaments anchorable to the inner wall of the blood vessel.